Decoy Therapeutics: Q2 Earnings Snapshot
Portfolio now spans seven patent families and 19 pending applications across seven jurisdictions, protecting antiviral peptide conjugates, the methods used to make them, their formulations, and the design...
Lead D-MAV demonstrates cross-viral family fusion inhibition, validating the platform; opens a new program in filovirus pandemic preparedness
CAMBRIDGE, Mass. , July 15, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered...
HOUSTON , June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category...
Rick Pierce to join speakers from Boehringer Ingelheim, RA Capital and ILiAD Biotechnologies for discussion on early clinical development
CAMBRIDGE, Mass. , June 3, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered...
Collaboration supports Phase 1 and Phase 2a human proof-of-concept studies for new antiviral category designed to address multiple viruses with a single adaptable therapeutic
Appointment deepens scientific leadership as Decoy advances its Designable Multi-Antiviral pipeline toward clinical development
Decoy Therapeutics: Q1 Earnings Snapshot